Pharmacokinetic Drug–Drug Interaction between Cilostazol and Rosuvastatin in Healthy Participants
American Journal of Cardiovascular Drugs · 2025
DOI: 10.1007/s40256-024-00686-w ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Cardiovascular Drugs, 2025. Verfasst von Dong Ho Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, Chungnam National University Hospital, 266 Munhwa-ro, Jung-gu, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Rosuvastatin Calcium, Cilostazol, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Tetrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Cilostazol improves ischemic symptoms and prevents recurrence following cerebral infarction, and rosuvastatin reduces cholesterol levels. However, no reports exist on the pharmacokinetic interactions between these two drugs in healthy adults. This study evaluated the pharmacokinetic (PK) interactions and safety of cilostazol and rosuvastatin when co-administered to healthy male participants. METHODS: A randomized, open-label, multiple-dosing, two-arm, two-period study was conducted. Arm A had 30 participants receiving 200 mg cilostazol daily and arm B had 27 participants receiving 20 mg rosuvastatin daily for 7 days. In period 2, both arms received a combination of 200 mg cilostazol and 20 mg rosuvastatin daily for 7 days following a 7-day washout period. Plasma concentrations of cilostazol, its metabolites, and rosuvastatin were quantified using liquid chromatography-tandem mass spectrometry. RESULTS: Fifty-seven participants were randomized, and 44 completed the study. The geometric mean ratio (GMR) and 90% confidence intervals (CI) for maximum plasma concentration at steady state (Cmax,ss) and area under the plasma concentration-time curve during the dosing interval at steady state (AUCtau,ss) indicated no significant interaction between cilostazol and rosuvastatin. Safety assessments showed comparable profiles to individual drug administration, with no significant adverse events. CONCLUSION: The repeated co-administration of cilostazol and rosuvastatin in healthy male participants resulted in minor PK interactions and exhibited a safety and tolerability profile similar to those of the individual drugs. This suggested that the combined regimen is well tolerated and does not necessitate dose adjustments. REGISTRATION: ClinicalTrials.Gov identifier no. NCT06568133.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Trials Center, Chungnam National University Hospital, 266 Munhwa-ro, Jung-gu, Daejeon, Republic of Korea.
- Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- Department of Pharmacology, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- Korea United Pharmaceutical Corporation, Seoul, Republic of Korea.
- Caleb Multilab Inc., Seoul, Republic of Korea.
- Department of Family Medicine, Chungnam National University Hospital, 266 Munhwa-ro, Jung-gu, Daejeon, Republic of Korea. jjg72@cnuh.co.kr.
Zitieren
APA
Kim, D. H., Hong, J. H., Jung, W. T., Nam, K. Y., Roh, J. S., Lee, H. J., Moon, J., Kim, K. Y., Jung, J. G., & Sunwoo, J. (2025). Pharmacokinetic Drug–Drug Interaction between Cilostazol and Rosuvastatin in Healthy Participants. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-024-00686-w
Vancouver
Kim DH, Hong JH, Jung WT, Nam KY, Roh JS, Lee HJ, et al. Pharmacokinetic Drug–Drug Interaction between Cilostazol and Rosuvastatin in Healthy Participants. American Journal of Cardiovascular Drugs. 2025. doi:10.1007/s40256-024-00686-w
BibTeX
@article{Kim2025,
author = {Kim, Dong Ho and Hong, Jang Hee and Jung, Won Tae and Nam, Kyu-Yeol and Roh, Jae Seok and Lee, Hye Jung and Moon, JungHa and Kim, Kyu Yeon and Jung, Jin-Gyu and Sunwoo, Jung},
title = {Pharmacokinetic Drug–Drug Interaction between Cilostazol and Rosuvastatin in Healthy Participants},
journal = {American Journal of Cardiovascular Drugs},
year = {2025},
doi = {10.1007/s40256-024-00686-w}
}
EUVIMED